Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer

Pharmacogenomics

Volumn 10, Issue 8, 2009, Pages 1277-1283

  Formento, Jean Louis ^a   Etienne Grimaldi, Marie Christine ^a   Francoual, Mireille ^a   Pagès, Gilles ^a   Onesto, Cercina ^a   Formento, Patricia ^a   Chamorey, Emmanuel ^a   Dassonville, Olivier ^a   Poissonnet, Gilles ^a   Milano, Gérard ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Angiogenesis; Gene polymorphism; Head and neck cancer; VEGF A

Indexed keywords

ADENINE; ANTINEOPLASTIC AGENT; CYTOSINE; GUANINE; THYMINE; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE LOCATION; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CANCER; HUMAN; MALE; NUCLEIC ACID BASE SUBSTITUTION; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70649102200     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.54     Document Type: Article

References (34)

1. Dvorak HF: Vascular permeability factor/ vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20(21), 4368-4380 (2002).
2. Salven P, Heikkilä P, Anttonen A, Kajanti M, Joensuu H: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod. Pathol. 10(11), 1128-1133 (1997). ■ Study reporting VEGF expression in inflammatory cells and normal adjacent tissues of squamous head and neck cancer. (Pubitemid 27521291)
3. Uehara M, Sano K, Ikeda H et al.: Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. Oral Oncol. 40(3), 321-325 (2004). (Pubitemid 38121570)
4. Onesto C, Hannoun-Lévi JM, Chamorey E, Formento JL, Ramaioli A, Pagès G: Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br. J. Cancer 94(10), 1516-1523 (2006). ■ Reports the prognostic value of tumoral VEGF-A expression in head and neck cancer patients. (Pubitemid 43772290)
5. Petersen I: Antiangiogenesis, anti-VEGF(R) and outlook. Recent Results Cancer Res. 176, 189-199 (2007).
6. Khosravi Shahi P, Fernández Pineda I: Tumoral angiogenesis: review of the literature. Cancer Invest. 26(1), 104-108 (2008).
7. Baka S, Clamp AR, Jayson GC: A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin. Ther. Targets. 10(6), 867-876 (2006). (Pubitemid 44816749)
8. Golshayan AR, Brick AJ, Choueiri TK: Predicting outcome to VEGF-targeted therapy in metastatic clear-cell renal cell carcinoma: data from recent studies. Future Oncol. 4(1), 85-92 (2008).
9. Longo R, Gasparini G: Anti-VEGF therapy: the search for clinical biomarkers. Expert Rev. Mol. Diagn. 8(3), 301-314 (2008). (Pubitemid 351724709)
10. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46(3), 293-298 (2004). (Pubitemid 39487303)
11. Krippl P, Langsenlehner U, Renner W et al.: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 106(4), 468-471 (2003). (Pubitemid 36966201)
12. Ku KT, Wan L, Peng HC, Tsai MH, Tsai CH, Tsai FJ: Vascular endothelial growth factor gene-460 C/T polymorphism is a biomarker for oral cancer. Oral Oncol. 41(5), 497-502 (2005). ■ Case-control study reporting that VEGF -1498T>C gene polymorphism (named -460T>C in the Ku study) is associated with oral cancer risk. (Pubitemid 40692850)
13. Lee SJ, Lee SY, Jeon HS et al.: Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol. Biomarkers Prev. 14(3), 571-575 (2005).
14. Heist RS, Zhai R, Liu G et al.: VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J. Clin. Oncol. 26(6), 856-862 (2008).
15. Lu H, Shu XO, Cui Y et al.: Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 65(12), 5015-5019 (2005). (Pubitemid 40827307)
16. Kim E-J, Jeong P, Quan C et al.: Genotypes of TNFa, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65(1), 70-75 (2005). (Pubitemid 40169608)
17. Watson CJ, Webb NJA, Bottomley MJ, Brenchley PEC: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene : correlation with variation in VEGF protein production. Cytokine 12(8), 1232-1235 (2000).
18. Kim JK, Oh D, Kwak SK et al.: Genetic polymorphism of vascular endothelial growth factor (VEGF C936T) in the Korean population. Korean J. Biol. Sci. 7, 261-264 (2003).
19. Seiwert TY, Cohen EE: Targeting angiogenesis in head and neck cancer. Semin. Oncol. 35(3), 274-285 (2008).
20. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37(6), 443-448 (2000). ■■ First study identifying the VEGF-A 936C>T gene polymorphism, and reporting its impact on VEGF plasma levels. (Pubitemid 32037619)
21. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW: Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63(4), 812-816 (2003). ■■ Experimental study establishing the impact of -1498T>C and -634G>C gene polymorphisms (namely -460 and +405, respectively in the Stevens study) on VEGF transcription. (Pubitemid 36231981)
22. Zhai R, Gong MN, Zhou W et al.: Genotypes and haplotypes of the VEGF gene are associated with higher mortality and lower VEGF plasma levels in patients with ARDS. Thorax 62(8), 718-722 (2007). (Pubitemid 47235018)
23. Hefler LA, Mustea A, Könsgen D et al.: Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin. Cancer Res. 13(3), 898-901 (2007). ■ Clinical study reporting that simultaneous carriage of -2578CC, -1154GG and -634CC VEGF-A genotypes was associated with a shortened survival in ovarian cancer patients.
24. Kim JG, Chae YS, Sohn SK et al.: Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin. Cancer Res. 14(1), 62-66 (2008). ■ Reports the impact of VEGF-A -634G>C and 936C>T gene polymorphisms on survival of colorectal cancer patients.
25. Schneider BP, Wang M, Radovich M et al.: Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26(28), 4672-4678 (2008). ■ Reports that VEGF-A -2578AA and -1154AA polymorphisms were both associated with longer survival in breast cancer patients receiving bevacizumab.
26. Jin Q, Hemminki K, Enquist K et al.: Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin. Cancer Res. 11(10), 3647-3653 (2005). ■ Large case-control study investigating the impact of VEGF-A -2578C>A, -1154G>A, -634G>C and 936C>T polymorphisms on breast cancer risk and tumor characteristics.
27. Mizukami Y, Kohgo Y, Chung DC: Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin. Cancer Res. 13(19), 5670-5674 (2007). (Pubitemid 47583891)
28. Smith TG, Robbins PA, Ratcliffe PJ: The human side of hypoxia-inducible factor. Br. J. Haematol. 141(3), 325-334 (2008).
29. Al-Moundhri MS, Al-Shukaili A, Al- Nabhani M et al.: Measurement of circulating levels of VEGF-A, -C, and -D and their receptors, VEGFR-1 and -2 in gastric adenocarcinoma. World J. Gastroenterol. 14(24), 3879-3883 (2008).
30. Klubo-Gwiezdzinska J, Junik R, Kopczynska E, Juraniec O, Kardymowicz H: The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter. Eur. J. Endocrinol. 157(4), 521-527 (2007). (Pubitemid 350018457)
31. Koh SH, Noh MY, Cho GW, Kim KS, Kim SH: Erythropoietin increases the motility of human bone marrow multipotent stromal cells (hBM-MSCs) and enhances the production of neurotrophic factors from hBM-MSCs. Stem Cells Dev. 18(3), 411-421 (2008).
32. Kagiwada H, Yashiki T, Ohshima A, Tadokoro M, Nagaya N, Ohgushi H: Human mesenchymal stem cells as a stable source of VEGF-producing cells. J. Tissue Eng. Regen. Med. 2(4), 184-189 (2008).
33. Levy AP, Levy NS, Goldberg MA: Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel- Lindau protein. J. Biol. Chem. 271(41), 25492-25497 (1996).
34. Innate Immunity in Heart, Lung and Blood Disease http://innateimmunity. net/IIPGA1